Bruker Corporation announced a major technological breakthrough on November 8, 2024, with the introduction of EpicIF (Enhanced photobleaching in cyclic immunofluorescence) technology for its CellScape™ Precise Spatial Proteomics platform. This innovation significantly expands the range of compatible commercially available fluorophore conjugated antibodies by nearly 10-fold.
EpicIF simplifies assay development and increases throughput by up to 2-fold, while preserving tissue integrity and maintaining a lack of cross-reactivity. The technology uses a proprietary reagent with visible light to gently erase fluorescence signals from a wide range of fluorophores.
This advancement builds on the CellScape platform's existing best-in-class resolution and high dynamic range imaging. EpicIF is supported by the concurrent release of new CellScape™ Navigator software, offering an intuitive user interface and easy experiment setup, and will be available as an upgrade to current CellScape instruments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.